Medical Care
RNAi for Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Apr 15, 24
- ID: 170672
- Pages: 112
- Figures: 188
- Views: 19
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
The global market for RNAi for Therapeutic was estimated to be worth US$ 176 million in 2023 and is forecast to a readjusted size of US$ 2218 million by 2030 with a CAGR of 43.1% during the forecast period 2024-2030
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of RNAi for Therapeutic by region & country, by Type, and by Application.
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Segment by Type:
siRNA
miRNA
shRNA
Segment by Application
Cancer
Cardiovascular
HBV
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of RNAi for Therapeutic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of RNAi for Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of RNAi for Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for RNAi for Therapeutic was estimated to be worth US$ 176 million in 2023 and is forecast to a readjusted size of US$ 2218 million by 2030 with a CAGR of 43.1% during the forecast period 2024-2030
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of RNAi for Therapeutic by region & country, by Type, and by Application.
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Segment by Type:
siRNA
miRNA
shRNA
Segment by Application
Cancer
Cardiovascular
HBV
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of RNAi for Therapeutic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of RNAi for Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of RNAi for Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 RNAi for Therapeutic Product Introduction
1.2 Global RNAi for Therapeutic Market Size Forecast
1.3 RNAi for Therapeutic Market Trends & Drivers
1.3.1 RNAi for Therapeutic Industry Trends
1.3.2 RNAi for Therapeutic Market Drivers & Opportunity
1.3.3 RNAi for Therapeutic Market Challenges
1.3.4 RNAi for Therapeutic Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global RNAi for Therapeutic Players Revenue Ranking (2023)
2.2 Global RNAi for Therapeutic Revenue by Company (2019-2024)
2.3 Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters
2.4 Key Companies RNAi for Therapeutic Product Offered
2.5 Key Companies Time to Begin Mass Production of RNAi for Therapeutic
2.6 RNAi for Therapeutic Market Competitive Analysis
2.6.1 RNAi for Therapeutic Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by RNAi for Therapeutic Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 siRNA
3.1.2 miRNA
3.1.3 shRNA
3.2 Global RNAi for Therapeutic Sales Value by Type
3.2.1 Global RNAi for Therapeutic Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global RNAi for Therapeutic Sales Value, by Type (2019-2030)
3.2.3 Global RNAi for Therapeutic Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cancer
4.1.2 Cardiovascular
4.1.3 HBV
4.1.4 Others
4.2 Global RNAi for Therapeutic Sales Value by Application
4.2.1 Global RNAi for Therapeutic Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global RNAi for Therapeutic Sales Value, by Application (2019-2030)
4.2.3 Global RNAi for Therapeutic Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global RNAi for Therapeutic Sales Value by Region
5.1.1 Global RNAi for Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global RNAi for Therapeutic Sales Value by Region (2019-2024)
5.1.3 Global RNAi for Therapeutic Sales Value by Region (2025-2030)
5.1.4 Global RNAi for Therapeutic Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America RNAi for Therapeutic Sales Value, 2019-2030
5.2.2 North America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe RNAi for Therapeutic Sales Value, 2019-2030
5.3.2 Europe RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific RNAi for Therapeutic Sales Value, 2019-2030
5.4.2 Asia Pacific RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America RNAi for Therapeutic Sales Value, 2019-2030
5.5.2 South America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa RNAi for Therapeutic Sales Value, 2019-2030
5.6.2 Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions RNAi for Therapeutic Sales Value
6.3 United States
6.3.1 United States RNAi for Therapeutic Sales Value, 2019-2030
6.3.2 United States RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.3.3 United States RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe RNAi for Therapeutic Sales Value, 2019-2030
6.4.2 Europe RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China RNAi for Therapeutic Sales Value, 2019-2030
6.5.2 China RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.5.3 China RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan RNAi for Therapeutic Sales Value, 2019-2030
6.6.2 Japan RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea RNAi for Therapeutic Sales Value, 2019-2030
6.7.2 South Korea RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia RNAi for Therapeutic Sales Value, 2019-2030
6.8.2 Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India RNAi for Therapeutic Sales Value, 2019-2030
6.9.2 India RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.9.3 India RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Profile
7.1.2 Alnylam Pharmaceuticals Main Business
7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
7.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.1.5 Alnylam Pharmaceuticals Recent Developments
7.2 Arbutus Biopharma (Tekmira)
7.2.1 Arbutus Biopharma (Tekmira) Profile
7.2.2 Arbutus Biopharma (Tekmira) Main Business
7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products, Services and Solutions
7.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.2.5 Arbutus Biopharma (Tekmira) Recent Developments
7.3 Arrowhead
7.3.1 Arrowhead Profile
7.3.2 Arrowhead Main Business
7.3.3 Arrowhead RNAi for Therapeutic Products, Services and Solutions
7.3.4 Arrowhead RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.3.5 Dicerna Pharmaceuticals Recent Developments
7.4 Dicerna Pharmaceuticals
7.4.1 Dicerna Pharmaceuticals Profile
7.4.2 Dicerna Pharmaceuticals Main Business
7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
7.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.4.5 Dicerna Pharmaceuticals Recent Developments
7.5 Mirna Therapeutics
7.5.1 Mirna Therapeutics Profile
7.5.2 Mirna Therapeutics Main Business
7.5.3 Mirna Therapeutics RNAi for Therapeutic Products, Services and Solutions
7.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.5.5 Mirna Therapeutics Recent Developments
7.6 Quark Pharmaceuticals
7.6.1 Quark Pharmaceuticals Profile
7.6.2 Quark Pharmaceuticals Main Business
7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
7.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.6.5 Quark Pharmaceuticals Recent Developments
7.7 RXi Pharmaceuticals
7.7.1 RXi Pharmaceuticals Profile
7.7.2 RXi Pharmaceuticals Main Business
7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
7.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.7.5 RXi Pharmaceuticals Recent Developments
7.8 Silence Therapeutics
7.8.1 Silence Therapeutics Profile
7.8.2 Silence Therapeutics Main Business
7.8.3 Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions
7.8.4 Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.8.5 Silence Therapeutics Recent Developments
7.9 Benitec Biopharma
7.9.1 Benitec Biopharma Profile
7.9.2 Benitec Biopharma Main Business
7.9.3 Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
7.9.4 Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.9.5 Benitec Biopharma Recent Developments
7.10 miRagen Therapeutics
7.10.1 miRagen Therapeutics Profile
7.10.2 miRagen Therapeutics Main Business
7.10.3 miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions
7.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.10.5 miRagen Therapeutics Recent Developments
7.11 Sylentis
7.11.1 Sylentis Profile
7.11.2 Sylentis Main Business
7.11.3 Sylentis RNAi for Therapeutic Products, Services and Solutions
7.11.4 Sylentis RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.11.5 Sylentis Recent Developments
7.12 Gradalis
7.12.1 Gradalis Profile
7.12.2 Gradalis Main Business
7.12.3 Gradalis RNAi for Therapeutic Products, Services and Solutions
7.12.4 Gradalis RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.12.5 Gradalis Recent Developments
7.13 Sirnaomics
7.13.1 Sirnaomics Profile
7.13.2 Sirnaomics Main Business
7.13.3 Sirnaomics RNAi for Therapeutic Products, Services and Solutions
7.13.4 Sirnaomics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.13.5 Sirnaomics Recent Developments
7.14 Silenseed
7.14.1 Silenseed Profile
7.14.2 Silenseed Main Business
7.14.3 Silenseed RNAi for Therapeutic Products, Services and Solutions
7.14.4 Silenseed RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.14.5 Silenseed Recent Developments
8 Industry Chain Analysis
8.1 RNAi for Therapeutic Industrial Chain
8.2 RNAi for Therapeutic Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 RNAi for Therapeutic Sales Model
8.5.2 Sales Channel
8.5.3 RNAi for Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 RNAi for Therapeutic Product Introduction
1.2 Global RNAi for Therapeutic Market Size Forecast
1.3 RNAi for Therapeutic Market Trends & Drivers
1.3.1 RNAi for Therapeutic Industry Trends
1.3.2 RNAi for Therapeutic Market Drivers & Opportunity
1.3.3 RNAi for Therapeutic Market Challenges
1.3.4 RNAi for Therapeutic Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global RNAi for Therapeutic Players Revenue Ranking (2023)
2.2 Global RNAi for Therapeutic Revenue by Company (2019-2024)
2.3 Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters
2.4 Key Companies RNAi for Therapeutic Product Offered
2.5 Key Companies Time to Begin Mass Production of RNAi for Therapeutic
2.6 RNAi for Therapeutic Market Competitive Analysis
2.6.1 RNAi for Therapeutic Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by RNAi for Therapeutic Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 siRNA
3.1.2 miRNA
3.1.3 shRNA
3.2 Global RNAi for Therapeutic Sales Value by Type
3.2.1 Global RNAi for Therapeutic Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global RNAi for Therapeutic Sales Value, by Type (2019-2030)
3.2.3 Global RNAi for Therapeutic Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cancer
4.1.2 Cardiovascular
4.1.3 HBV
4.1.4 Others
4.2 Global RNAi for Therapeutic Sales Value by Application
4.2.1 Global RNAi for Therapeutic Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global RNAi for Therapeutic Sales Value, by Application (2019-2030)
4.2.3 Global RNAi for Therapeutic Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global RNAi for Therapeutic Sales Value by Region
5.1.1 Global RNAi for Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global RNAi for Therapeutic Sales Value by Region (2019-2024)
5.1.3 Global RNAi for Therapeutic Sales Value by Region (2025-2030)
5.1.4 Global RNAi for Therapeutic Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America RNAi for Therapeutic Sales Value, 2019-2030
5.2.2 North America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe RNAi for Therapeutic Sales Value, 2019-2030
5.3.2 Europe RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific RNAi for Therapeutic Sales Value, 2019-2030
5.4.2 Asia Pacific RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America RNAi for Therapeutic Sales Value, 2019-2030
5.5.2 South America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa RNAi for Therapeutic Sales Value, 2019-2030
5.6.2 Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions RNAi for Therapeutic Sales Value
6.3 United States
6.3.1 United States RNAi for Therapeutic Sales Value, 2019-2030
6.3.2 United States RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.3.3 United States RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe RNAi for Therapeutic Sales Value, 2019-2030
6.4.2 Europe RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China RNAi for Therapeutic Sales Value, 2019-2030
6.5.2 China RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.5.3 China RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan RNAi for Therapeutic Sales Value, 2019-2030
6.6.2 Japan RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea RNAi for Therapeutic Sales Value, 2019-2030
6.7.2 South Korea RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia RNAi for Therapeutic Sales Value, 2019-2030
6.8.2 Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India RNAi for Therapeutic Sales Value, 2019-2030
6.9.2 India RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
6.9.3 India RNAi for Therapeutic Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Profile
7.1.2 Alnylam Pharmaceuticals Main Business
7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
7.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.1.5 Alnylam Pharmaceuticals Recent Developments
7.2 Arbutus Biopharma (Tekmira)
7.2.1 Arbutus Biopharma (Tekmira) Profile
7.2.2 Arbutus Biopharma (Tekmira) Main Business
7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products, Services and Solutions
7.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.2.5 Arbutus Biopharma (Tekmira) Recent Developments
7.3 Arrowhead
7.3.1 Arrowhead Profile
7.3.2 Arrowhead Main Business
7.3.3 Arrowhead RNAi for Therapeutic Products, Services and Solutions
7.3.4 Arrowhead RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.3.5 Dicerna Pharmaceuticals Recent Developments
7.4 Dicerna Pharmaceuticals
7.4.1 Dicerna Pharmaceuticals Profile
7.4.2 Dicerna Pharmaceuticals Main Business
7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
7.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.4.5 Dicerna Pharmaceuticals Recent Developments
7.5 Mirna Therapeutics
7.5.1 Mirna Therapeutics Profile
7.5.2 Mirna Therapeutics Main Business
7.5.3 Mirna Therapeutics RNAi for Therapeutic Products, Services and Solutions
7.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.5.5 Mirna Therapeutics Recent Developments
7.6 Quark Pharmaceuticals
7.6.1 Quark Pharmaceuticals Profile
7.6.2 Quark Pharmaceuticals Main Business
7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
7.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.6.5 Quark Pharmaceuticals Recent Developments
7.7 RXi Pharmaceuticals
7.7.1 RXi Pharmaceuticals Profile
7.7.2 RXi Pharmaceuticals Main Business
7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
7.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.7.5 RXi Pharmaceuticals Recent Developments
7.8 Silence Therapeutics
7.8.1 Silence Therapeutics Profile
7.8.2 Silence Therapeutics Main Business
7.8.3 Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions
7.8.4 Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.8.5 Silence Therapeutics Recent Developments
7.9 Benitec Biopharma
7.9.1 Benitec Biopharma Profile
7.9.2 Benitec Biopharma Main Business
7.9.3 Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
7.9.4 Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.9.5 Benitec Biopharma Recent Developments
7.10 miRagen Therapeutics
7.10.1 miRagen Therapeutics Profile
7.10.2 miRagen Therapeutics Main Business
7.10.3 miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions
7.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.10.5 miRagen Therapeutics Recent Developments
7.11 Sylentis
7.11.1 Sylentis Profile
7.11.2 Sylentis Main Business
7.11.3 Sylentis RNAi for Therapeutic Products, Services and Solutions
7.11.4 Sylentis RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.11.5 Sylentis Recent Developments
7.12 Gradalis
7.12.1 Gradalis Profile
7.12.2 Gradalis Main Business
7.12.3 Gradalis RNAi for Therapeutic Products, Services and Solutions
7.12.4 Gradalis RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.12.5 Gradalis Recent Developments
7.13 Sirnaomics
7.13.1 Sirnaomics Profile
7.13.2 Sirnaomics Main Business
7.13.3 Sirnaomics RNAi for Therapeutic Products, Services and Solutions
7.13.4 Sirnaomics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.13.5 Sirnaomics Recent Developments
7.14 Silenseed
7.14.1 Silenseed Profile
7.14.2 Silenseed Main Business
7.14.3 Silenseed RNAi for Therapeutic Products, Services and Solutions
7.14.4 Silenseed RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)
7.14.5 Silenseed Recent Developments
8 Industry Chain Analysis
8.1 RNAi for Therapeutic Industrial Chain
8.2 RNAi for Therapeutic Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 RNAi for Therapeutic Sales Model
8.5.2 Sales Channel
8.5.3 RNAi for Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. RNAi for Therapeutic Market Trends
Table 2. RNAi for Therapeutic Market Drivers & Opportunity
Table 3. RNAi for Therapeutic Market Challenges
Table 4. RNAi for Therapeutic Market Restraints
Table 5. Global RNAi for Therapeutic Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global RNAi for Therapeutic Revenue Market Share by Company (2019-2024)
Table 7. Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters
Table 8. Key Companies RNAi for Therapeutic Product Type
Table 9. Key Companies Time to Begin Mass Production of RNAi for Therapeutic
Table 10. Global RNAi for Therapeutic Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global RNAi for Therapeutic Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global RNAi for Therapeutic Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global RNAi for Therapeutic Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global RNAi for Therapeutic Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global RNAi for Therapeutic Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global RNAi for Therapeutic Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global RNAi for Therapeutic Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global RNAi for Therapeutic Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global RNAi for Therapeutic Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global RNAi for Therapeutic Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global RNAi for Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global RNAi for Therapeutic Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global RNAi for Therapeutic Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global RNAi for Therapeutic Sales Value by Region (2019-2024) & (%)
Table 27. Global RNAi for Therapeutic Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions RNAi for Therapeutic Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions RNAi for Therapeutic Sales Value, (2025-2030) & (US$ Million)
Table 31. Alnylam Pharmaceuticals Basic Information List
Table 32. Alnylam Pharmaceuticals Description and Business Overview
Table 33. Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
Table 34. Revenue (US$ Million) in RNAi for Therapeutic Business of Alnylam Pharmaceuticals (2019-2024)
Table 35. Alnylam Pharmaceuticals Recent Developments
Table 36. Arbutus Biopharma (Tekmira) Basic Information List
Table 37. Arbutus Biopharma (Tekmira) Description and Business Overview
Table 38. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products, Services and Solutions
Table 39. Revenue (US$ Million) in RNAi for Therapeutic Business of Arbutus Biopharma (Tekmira) (2019-2024)
Table 40. Arbutus Biopharma (Tekmira) Recent Developments
Table 41. Arrowhead Basic Information List
Table 42. Arrowhead Description and Business Overview
Table 43. Arrowhead RNAi for Therapeutic Products, Services and Solutions
Table 44. Revenue (US$ Million) in RNAi for Therapeutic Business of Arrowhead (2019-2024)
Table 45. Arrowhead Recent Developments
Table 46. Dicerna Pharmaceuticals Basic Information List
Table 47. Dicerna Pharmaceuticals Description and Business Overview
Table 48. Dicerna Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
Table 49. Revenue (US$ Million) in RNAi for Therapeutic Business of Dicerna Pharmaceuticals (2019-2024)
Table 50. Dicerna Pharmaceuticals Recent Developments
Table 51. Mirna Therapeutics Basic Information List
Table 52. Mirna Therapeutics Description and Business Overview
Table 53. Mirna Therapeutics RNAi for Therapeutic Products, Services and Solutions
Table 54. Revenue (US$ Million) in RNAi for Therapeutic Business of Mirna Therapeutics (2019-2024)
Table 55. Mirna Therapeutics Recent Developments
Table 56. Quark Pharmaceuticals Basic Information List
Table 57. Quark Pharmaceuticals Description and Business Overview
Table 58. Quark Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
Table 59. Revenue (US$ Million) in RNAi for Therapeutic Business of Quark Pharmaceuticals (2019-2024)
Table 60. Quark Pharmaceuticals Recent Developments
Table 61. RXi Pharmaceuticals Basic Information List
Table 62. RXi Pharmaceuticals Description and Business Overview
Table 63. RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
Table 64. Revenue (US$ Million) in RNAi for Therapeutic Business of RXi Pharmaceuticals (2019-2024)
Table 65. RXi Pharmaceuticals Recent Developments
Table 66. Silence Therapeutics Basic Information List
Table 67. Silence Therapeutics Description and Business Overview
Table 68. Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions
Table 69. Revenue (US$ Million) in RNAi for Therapeutic Business of Silence Therapeutics (2019-2024)
Table 70. Silence Therapeutics Recent Developments
Table 71. Benitec Biopharma Basic Information List
Table 72. Benitec Biopharma Description and Business Overview
Table 73. Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
Table 74. Revenue (US$ Million) in RNAi for Therapeutic Business of Benitec Biopharma (2019-2024)
Table 75. Benitec Biopharma Recent Developments
Table 76. miRagen Therapeutics Basic Information List
Table 77. miRagen Therapeutics Description and Business Overview
Table 78. miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions
Table 79. Revenue (US$ Million) in RNAi for Therapeutic Business of miRagen Therapeutics (2019-2024)
Table 80. miRagen Therapeutics Recent Developments
Table 81. Sylentis Basic Information List
Table 82. Sylentis Description and Business Overview
Table 83. Sylentis RNAi for Therapeutic Products, Services and Solutions
Table 84. Revenue (US$ Million) in RNAi for Therapeutic Business of Sylentis (2019-2024)
Table 85. Sylentis Recent Developments
Table 86. Gradalis Basic Information List
Table 87. Gradalis Description and Business Overview
Table 88. Gradalis RNAi for Therapeutic Products, Services and Solutions
Table 89. Revenue (US$ Million) in RNAi for Therapeutic Business of Gradalis (2019-2024)
Table 90. Gradalis Recent Developments
Table 91. Sirnaomics Basic Information List
Table 92. Sirnaomics Description and Business Overview
Table 93. Sirnaomics RNAi for Therapeutic Products, Services and Solutions
Table 94. Revenue (US$ Million) in RNAi for Therapeutic Business of Sirnaomics (2019-2024)
Table 95. Sirnaomics Recent Developments
Table 96. Silenseed Basic Information List
Table 97. Silenseed Description and Business Overview
Table 98. Silenseed RNAi for Therapeutic Products, Services and Solutions
Table 99. Revenue (US$ Million) in RNAi for Therapeutic Business of Silenseed (2019-2024)
Table 100. Silenseed Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. RNAi for Therapeutic Downstream Customers
Table 104. RNAi for Therapeutic Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. RNAi for Therapeutic Product Picture
Figure 2. Global RNAi for Therapeutic Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 4. RNAi for Therapeutic Report Years Considered
Figure 5. Global RNAi for Therapeutic Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by RNAi for Therapeutic Revenue in 2023
Figure 7. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. siRNA Picture
Figure 9. miRNA Picture
Figure 10. shRNA Picture
Figure 11. Global RNAi for Therapeutic Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global RNAi for Therapeutic Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of Cancer
Figure 14. Product Picture of Cardiovascular
Figure 15. Product Picture of HBV
Figure 16. Product Picture of Others
Figure 17. Global RNAi for Therapeutic Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global RNAi for Therapeutic Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 20. North America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 25. South America RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 26. South America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions RNAi for Therapeutic Sales Value (%), (2019-2030)
Figure 30. United States RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 32. United States RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 36. China RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 37. China RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 38. China RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 48. India RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 49. India RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 50. India RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 51. RNAi for Therapeutic Industrial Chain
Figure 52. RNAi for Therapeutic Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Table 1. RNAi for Therapeutic Market Trends
Table 2. RNAi for Therapeutic Market Drivers & Opportunity
Table 3. RNAi for Therapeutic Market Challenges
Table 4. RNAi for Therapeutic Market Restraints
Table 5. Global RNAi for Therapeutic Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global RNAi for Therapeutic Revenue Market Share by Company (2019-2024)
Table 7. Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters
Table 8. Key Companies RNAi for Therapeutic Product Type
Table 9. Key Companies Time to Begin Mass Production of RNAi for Therapeutic
Table 10. Global RNAi for Therapeutic Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global RNAi for Therapeutic Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global RNAi for Therapeutic Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global RNAi for Therapeutic Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global RNAi for Therapeutic Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global RNAi for Therapeutic Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global RNAi for Therapeutic Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global RNAi for Therapeutic Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global RNAi for Therapeutic Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global RNAi for Therapeutic Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global RNAi for Therapeutic Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global RNAi for Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global RNAi for Therapeutic Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global RNAi for Therapeutic Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global RNAi for Therapeutic Sales Value by Region (2019-2024) & (%)
Table 27. Global RNAi for Therapeutic Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions RNAi for Therapeutic Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions RNAi for Therapeutic Sales Value, (2025-2030) & (US$ Million)
Table 31. Alnylam Pharmaceuticals Basic Information List
Table 32. Alnylam Pharmaceuticals Description and Business Overview
Table 33. Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
Table 34. Revenue (US$ Million) in RNAi for Therapeutic Business of Alnylam Pharmaceuticals (2019-2024)
Table 35. Alnylam Pharmaceuticals Recent Developments
Table 36. Arbutus Biopharma (Tekmira) Basic Information List
Table 37. Arbutus Biopharma (Tekmira) Description and Business Overview
Table 38. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products, Services and Solutions
Table 39. Revenue (US$ Million) in RNAi for Therapeutic Business of Arbutus Biopharma (Tekmira) (2019-2024)
Table 40. Arbutus Biopharma (Tekmira) Recent Developments
Table 41. Arrowhead Basic Information List
Table 42. Arrowhead Description and Business Overview
Table 43. Arrowhead RNAi for Therapeutic Products, Services and Solutions
Table 44. Revenue (US$ Million) in RNAi for Therapeutic Business of Arrowhead (2019-2024)
Table 45. Arrowhead Recent Developments
Table 46. Dicerna Pharmaceuticals Basic Information List
Table 47. Dicerna Pharmaceuticals Description and Business Overview
Table 48. Dicerna Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
Table 49. Revenue (US$ Million) in RNAi for Therapeutic Business of Dicerna Pharmaceuticals (2019-2024)
Table 50. Dicerna Pharmaceuticals Recent Developments
Table 51. Mirna Therapeutics Basic Information List
Table 52. Mirna Therapeutics Description and Business Overview
Table 53. Mirna Therapeutics RNAi for Therapeutic Products, Services and Solutions
Table 54. Revenue (US$ Million) in RNAi for Therapeutic Business of Mirna Therapeutics (2019-2024)
Table 55. Mirna Therapeutics Recent Developments
Table 56. Quark Pharmaceuticals Basic Information List
Table 57. Quark Pharmaceuticals Description and Business Overview
Table 58. Quark Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
Table 59. Revenue (US$ Million) in RNAi for Therapeutic Business of Quark Pharmaceuticals (2019-2024)
Table 60. Quark Pharmaceuticals Recent Developments
Table 61. RXi Pharmaceuticals Basic Information List
Table 62. RXi Pharmaceuticals Description and Business Overview
Table 63. RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
Table 64. Revenue (US$ Million) in RNAi for Therapeutic Business of RXi Pharmaceuticals (2019-2024)
Table 65. RXi Pharmaceuticals Recent Developments
Table 66. Silence Therapeutics Basic Information List
Table 67. Silence Therapeutics Description and Business Overview
Table 68. Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions
Table 69. Revenue (US$ Million) in RNAi for Therapeutic Business of Silence Therapeutics (2019-2024)
Table 70. Silence Therapeutics Recent Developments
Table 71. Benitec Biopharma Basic Information List
Table 72. Benitec Biopharma Description and Business Overview
Table 73. Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
Table 74. Revenue (US$ Million) in RNAi for Therapeutic Business of Benitec Biopharma (2019-2024)
Table 75. Benitec Biopharma Recent Developments
Table 76. miRagen Therapeutics Basic Information List
Table 77. miRagen Therapeutics Description and Business Overview
Table 78. miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions
Table 79. Revenue (US$ Million) in RNAi for Therapeutic Business of miRagen Therapeutics (2019-2024)
Table 80. miRagen Therapeutics Recent Developments
Table 81. Sylentis Basic Information List
Table 82. Sylentis Description and Business Overview
Table 83. Sylentis RNAi for Therapeutic Products, Services and Solutions
Table 84. Revenue (US$ Million) in RNAi for Therapeutic Business of Sylentis (2019-2024)
Table 85. Sylentis Recent Developments
Table 86. Gradalis Basic Information List
Table 87. Gradalis Description and Business Overview
Table 88. Gradalis RNAi for Therapeutic Products, Services and Solutions
Table 89. Revenue (US$ Million) in RNAi for Therapeutic Business of Gradalis (2019-2024)
Table 90. Gradalis Recent Developments
Table 91. Sirnaomics Basic Information List
Table 92. Sirnaomics Description and Business Overview
Table 93. Sirnaomics RNAi for Therapeutic Products, Services and Solutions
Table 94. Revenue (US$ Million) in RNAi for Therapeutic Business of Sirnaomics (2019-2024)
Table 95. Sirnaomics Recent Developments
Table 96. Silenseed Basic Information List
Table 97. Silenseed Description and Business Overview
Table 98. Silenseed RNAi for Therapeutic Products, Services and Solutions
Table 99. Revenue (US$ Million) in RNAi for Therapeutic Business of Silenseed (2019-2024)
Table 100. Silenseed Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. RNAi for Therapeutic Downstream Customers
Table 104. RNAi for Therapeutic Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. RNAi for Therapeutic Product Picture
Figure 2. Global RNAi for Therapeutic Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 4. RNAi for Therapeutic Report Years Considered
Figure 5. Global RNAi for Therapeutic Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by RNAi for Therapeutic Revenue in 2023
Figure 7. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. siRNA Picture
Figure 9. miRNA Picture
Figure 10. shRNA Picture
Figure 11. Global RNAi for Therapeutic Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global RNAi for Therapeutic Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of Cancer
Figure 14. Product Picture of Cardiovascular
Figure 15. Product Picture of HBV
Figure 16. Product Picture of Others
Figure 17. Global RNAi for Therapeutic Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global RNAi for Therapeutic Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 20. North America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 25. South America RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 26. South America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions RNAi for Therapeutic Sales Value (%), (2019-2030)
Figure 30. United States RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 32. United States RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 36. China RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 37. China RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 38. China RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 48. India RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 49. India RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 50. India RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 51. RNAi for Therapeutic Industrial Chain
Figure 52. RNAi for Therapeutic Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232